The purpose of this research is to evaluate the incidence, time to development, imaging patterns, risk factors, and clinical significance of large vessel cerebral vasculopathy in pediatric patients with brain tumors treated with proton radiotherapy.
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INTRODUCTION
Radiotherapy is one of the primary therapies used to treat pediatric brain tumors.
Potential adverse effects of radiotherapy on the brain include radiation necrosis, atrophy, gliosis, telangiectasia, cavernous malformations, and vasculopathy. Radiation-induced cerebral vasculopathy is relatively uncommon but has reported following conventional photon radiotherapy for pediatric brain tumors, most commonly gliomas, and medulloblastomas. 1 Radiation-induced vasculopathy histologically demonstrates subintimal foam cells and myointimal proliferation, fibrous thickening and hyalinization of the subintima, thickening of the elastica, fibrous thickening of the adventitia, and loose connective tissue thickening occluding the lumen. 2 A correlation between radiation dose and age at radiotherapy with development of radiation-induced vasculopathy has been previously reported. 1, 3 Although radiation-induced vasculopathy can be diagnosed on histopathology, the diagnosis is primarily made by radiological evidence of arterial stenosis or occlusion of a large intracranial vessel that was previously normal prior to radiotherapy.
Compared with conventional (photon) radiation therapy, proton beam radiotherapy (PBT) offers the advantages of the absence of an exit dose, a highly conformal dose distribution, and a reduced radiation dose to adjacent normal tissue. 4 Therefore, potential benefits of PBT in patients with pediatric brain tumors may include the reduction of negative long-term effects of radiation, such as cognitive deficits, endocrine abnormalities, vascular abnormalities, and secondary malignancies. 5 PBT has been used increasingly to treat pediatric brain tumors, including craniopharyngiomas, ependymomas, germinomas, and medulloblastomas; however, radiation-induced large vessel cerebral vasculopathy (RLVCV) has been reported in only a few M A N U S C R I P T
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3 patients with PBT suggesting the complication is rare or yet to be fully evaluated in the literature. [6] [7] [8] [9] [10] [11] [12] Therefore, we evaluated the incidence, timing, imaging patterns, risk factors, and clinical significance of RLVCV in a cohort of pediatric patients with brain tumors treated with PBT.
MATERIALS AND METHODS
Following institutional review board approval, a retrospective study was performed from 
RESULTS
Patient characteristics are listed in Table 1 . A total of 5/75 (6.7%) of patients developed RLVCV. The median follow-up duration was 4.3 years (mean 4.2 years, range 0.6-9.6 years).
Among the four patients with RLCVC, intracranial pathology consisted of craniopharyngioma The patient with the pontine infarct was lost to follow-up. One patient died 26 months after the diagnosis of radiation-induced vasculopathy secondary to tumor recurrence.
None of the patients with LVCV had acute intracranial hemorrhage, intracranial aneurysm, or neurofibromatosis type-1. Among patients with LVCV, none were retrospectively identified on preceding MRI T2W or post contrast T1W MPRAGE sequences that were performed at a range of 2-6 months previously. Among patients without LVCV, none were identified to have clinically asymptomatic arterial stenosis on T2W or post contrast T1W MPRAGE.
DISCUSSION
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To our knowledge, this study is the largest series of RLVCV associated with PBT. In this study the crude incidence of RLVCV was approximately 6.7%, median time to development was 1.5 years (mean 3.0 years; range 1-7.5 years), and median age at time of PBT was 5.1 years. In comparison, reported photon radiotherapy large vessel vasculopathy demonstrates median time to development of 5 years (range 0.3-27 years), and median age at time of radiotherapy of 4.83 years. 1 The incidence of vasculopathy in our study was less than that reported by Omura et al who reported large vessel vasculopathy in 6/32 (19%) of pediatric patients with primary brain tumors in whom photon radiation fields included the circle of Willis and large intracranial vessels although this study had median follow up duration of 5.2 years. 3 Further studies are necessary to determine whether this difference in incidence reflects a reduction in large vessel vasculopathy with PBT compared to photon radiotherapy. At this time there is no reason to anticipate a difference in toxicity, including RLVCV, to normal tissues within a radiation treatment volume receiving a given dose, whether that dose was delivered by photon or PBT. We cannot assess whether the risk of RLVCV outside the target volume may be lower with PBT versus photon therapy, although the dose reduction to non-target tissues achieved by PBT may reduce the risk.
The vasculature of pediatric patients is suspected to be more susceptible to effects of radiotherapy. 13 In this study we are unable to demonstrate radiotherapy dose and age are risk factors for large vessel vasculopathy from PBT, although these results are likely due to the low incidence and our study may be helpful as more studies report results on radiation-induced vasculopathy with PBT. Omura et al performed a single institution evaluation of radiation induced large vessel vasculopathy and were able to demonstrate that increasing radiation dose was a risk factor but similarly could not determine if age was a risk factor, likely due to the low M A N U S C R I P T
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incidence of large vessel vasculopathy at their single institution similar to our study. 3 Wang et al, however, evaluated 77 reports of large vessel vasculopathy in pediatric patients with brain tumors treated with conventional radiotherapy and were able to demonstrate that younger age was a risk factor. 1 We suspect that younger age and higher radiation dose remain risk factors for development of large vessel vasculopathy with PBT based on data from conventional radiotherapy, but further reports of patients with large vessel vasculopathy from PBT will be necessary to reach this conclusion.
Radiation-induced vasculopathy has been reported to result in acute ischemic infarct, intraparenchymal hemorrhage, and aneurysm. [14] [15] [16] [17] [18] This study demonstrates that a majority of patients with RLVCV will present with acute stroke, often with significant permanent neurological deficit, and may require surgical treatment to promote collateral vessel formation.
Campen et al reported a 100-fold increase in risk of transient ischemic attack or stroke compared
to the general population, a median time of 4.9 years from initial radiation to time of stroke, and an increased risk of stroke in patients with radiation therapy to the circle of Willis. 14 Similarly,
El-Fayech et al demonstrated that radiation doses of 10 Gy or more to the circle of Willis was associated with a cumulative stroke incidence of 11.3% compared to an expected incidence of 1% in the general population. 19 Our study, similar to other studies, is unable to determine what additional genetic or metabolic factors may contribute to the vasculopathy. Lastly, although RLVCV and radiation-induced Moyamoya are generally considered synonymous, we chose the term RLVCV rather than radiation-induced Moyamoya for purposes of consistency with the majority of the literature on this subject, and because the majority of these patients do not exhibit significant collateral vessel formation like patients with Moyamoya vasculopathy. The lack of extensive collateral vessel formation suggests the stenosis may progress more rapidly than M A N U S C R I P T
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Moyamoya and likely accounts for the large areas of infarct encountered in some patients. This may also account for our inability to identify progressive stenosis occurring within the large arteries on MRIs prior to acute presentation of stroke and arterial stenosis or occlusion.
As the number of PBT centers increases, it is important that physicians are aware of the potential for RLVCV in pediatric patients treated with PBT, particularly tumors near the circle of 
